Meeting
2022 ASCO Annual Meeting
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).
Authors
Eric Van Cutsem
University Hospitals Leuven, Leuven, Belgium
Eric Van Cutsem , Rikke Løvendahl Eefsen , Sebastian Ochsenreither , Zanete Zvirbule , Audrius Ivanauskas , Dirk Arnold , Edita Baltruskeviciene , Per Pfeiffer , Jeffrey Yachnin , Rocio Garcia-Carbonero , Richard Greil , Christiane Jungels , Laurids Poulsen , Ahmad Awada , Ignacio Garcia-Ribas , Nedjad Losic , Joelle Collignon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03267316
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4141)
DOI
10.1200/JCO.2022.40.16_suppl.4141
Abstract #
4141
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
First Author: Astrid Paulus
Poster
2022 ASCO Annual Meeting
A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
First Author: Benjamin Leon Musher
Poster
2020 Gastrointestinal Cancers Symposium
A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
First Author: Benjamin Leon Musher
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).
First Author: Philippa Corrie